Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 4, 2009, Pages 375-380

  Fumoleau, Pierre ^a   Cortés Funes, Hernan ^b   Taleb, Amina B ^c   Chan, Stephen ^d   Campone, Mario ^e   Pouget, Jean Christophe ^c   Tubiana Hulin, Michèle ^f   Slabber, Conrad F ^g   Caroff Paraïso, Isabelle ^c,j   Alberts, Albert S ^h   Ben Ayed, Farhat ⁱ  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f CENTRE RENÉ HUGUENIN   (France)

^g STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^h Wilgers Hospital   (South Africa)

ⁱ SALAH AZAIEZ INSTITUTE   (Tunisia)

^j NONE   (France)

more..

Author keywords

Anthracycline taxane failure; Metastatic breast cancer; Third line; Vinflunine

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; TAXANE DERIVATIVE; VINFLUNINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; ILEUS; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; TAXOIDS; TREATMENT FAILURE; VINBLASTINE;

EID: 69349085207     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31818f2d2f     Document Type: Article

References (31)

1. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist. 2004;9:617-632. (Pubitemid 39546403)
2. Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist. 2001;6:56-64.
3. Wist EA, Sommer HH, Ostenstad B, et al. Oral capecitabine in anthracyclineand taxane-pretreated advanced/metastatic breast cancer. Acta Oncol. 2004;43:186-189. (Pubitemid 38478906)
4. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40:536-542. (Pubitemid 38220770)
5. Fahy J, Duflos A, Ribet JP, et al. Vinca alkaloids in superacidic media: a method for creating a new family of antitumor derivatives. J Am Chem Soc. 1997;119:8576-8577. (Pubitemid 27404589)
6. Ngan VK, Bellman K, Panda D, et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000;60:5045-5051. (Pubitemid 30739758)
7. Shnyder SD. Vinflunine. IDrugs. 2004;7:851-859.
8. Kruczynski A, Poli M, Dossi R, et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006;42:2821-2832. (Pubitemid 44584664)
9. Jean-Decoster C, Brichese L, Barret JM, et al. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anticancer Drugs. 1999;10:537-543. (Pubitemid 29410800)
10. Lobert S, Ingram JW, Hill BT, et al. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol. 1998;53:908-915. (Pubitemid 28244079)
11. Lobert S, Correia JJ. Energetics of vinca alkaloid interactions with tubulin. Methods Enzymol. 2000;323:77-103. (Pubitemid 34193274)
12. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/ taxane-based chemotherapy. Br J Cancer. 2006;95:1161-1166. (Pubitemid 44658478)
13. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006;94:1395-1401. (Pubitemid 43772272)
14. Bennouna J, Breton JL, Tourani JM, et al. Vinflunine - an active chemotherapy for treatment of advanced nonsmall-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer. 2006;94:1383-1388. (Pubitemid 43772270)
15. Hill BT, Fiebig HH, Waud WR, et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer. 1999;35:512-520.
16. Etievant C, Barret JM, Kruczynski A, et al. Vinflunine (20′,20′-difluoro- 3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in Pglycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs. 1998;16:3-17. (Pubitemid 28379411)
17. Etievant C, Kruczynski A, Barret JM, et al. Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro- 3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol. 2001;48:62-70. (Pubitemid 32662438)
18. Johnson P, Geldart T, Fumoleau P, et al. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs. 2006;24:223-231. (Pubitemid 43738961)
19. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143-151.
20. Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol. 2003;14:630-637. (Pubitemid 41295094)
21. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485-493. (Pubitemid 29075232)
22. Blum JL, Dieras V, LO Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759-1768. (Pubitemid 32952493)
23. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda® ) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003;14:1227-1233. (Pubitemid 37039048)
24. Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology. 2003;64:191-206. (Pubitemid 36438803)
25. Modi S, Currie VE, Seidman AD, et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer. 2005;6:55-60. (Pubitemid 40872947)
26. Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005;90:215-221. (Pubitemid 40576834)
27. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol. 1994;5:423-426. (Pubitemid 24159646)
28. Livingston RB, Ellis GK, Gralow JR, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997;15:1395-1400.
29. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001;92:2267-2272. (Pubitemid 33029069)
30. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23:2726-2734. (Pubitemid 46179462)
31. Dieing A, Georgieva G, Schmid P, et al. Benefit of cytostatic therapy in 3rd and following line in metastatic breast cancer, ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23:16S. Abstract 742.